

.....  
**Selected references from Prescrire's literature search.**

1- "Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004" *Official Journal of the European Union* of 27 December 2006: L378/1-L378/19.

2- Prescrire Editorial Staff "Application of the European regulation on paediatric drugs: remain vigilant!" *Prescrire Int* 2008; **17** (93): 38-41.

3- European Commission - Health and Consumers Directorate-General "General report on experience acquired as a result of the application of the Paediatric Regulation (Article 50(2) of Regulation (EC) No 1901/2006). "Experience acquired" and "lessons learnt" submitted for public consultation - Deadline for public consultation 28 November 2012" 18 September 2012: 13 pages.

4- Prescrire Editorial Staff "Who benefits from the European Paediatric Regulation?"

Response to the European Commission's public consultation on the lessons learnt from the first 5 years of application of the Paediatric Regulation" Paris, 28 November 2012. english.prescrire.org accessed 18 December 2012: 6 pages.

Translated from *Rev Prescrire* June 2013; **33** (356): 455

## The powerful influence of pharmaceutical sales representatives

It has long been established that visits by pharmaceutical sales representatives have a detrimental effect on the quality and cost of prescriptions (1,2). It is best not to underestimate their influence, while the pharmaceutical industry and French Ministry of Health continue to legitimise these visits through the "Sales Visit Charter", a code of conduct establishing norms for sales visits (3).

**A survey of 179 doctors in Brittany (France).** A study conducted in Brittany in 2009-2010 provides a concrete example of the influence that pharmaceutical representative visits have on doctors (4). Through telephone interviews, a profile was drawn up of 179 doctors selected at random from the 2950 general practitioners in Brittany. Information was collected on the frequency of meetings with pharmaceutical sales representatives, continuing education habits, type of medical practice and relationships with pharmaceutical companies. These doctors were then divided into 6 groups, based on the frequency of meetings with pharmaceutical sales representatives (4).

The Rennes regional state health insurance office (CRAM) then supplied aggregated data for the 6 groups, which were used to analyse their prescribing behaviour, including: the cost and number of prescriptions, and the drugs they tended to prescribe within certain pharmacotherapeutic groups (4).

**Measurable industry influence.** According to this study, the doctors who met most frequently with pharmaceutical sales representatives conducted shorter consultations with their patients and more consultations per day. They had been in practice longer, were more likely to read free medical journals and less likely to read medical journals requiring a subscription (4).

These doctors prescribed more angiotensin II receptor blockers, glitazones, gliptins (dipeptidyl peptidase-4 inhibitors) and certain antibiotics such as *moxifloxacin*, *levofloxacin* and *telithromycin* within their respective therapeutic classes (4). All of these drugs are promoted by pharmaceutical sales representatives at the expense of better evaluated, safer or cheaper alternatives.

This study also showed a statistically significant correlation between the fre-

quency of meetings with pharmaceutical sales representatives, and the number and cost of their prescriptions (4).

**Refuse to see pharmaceutical sales representatives in the interest of better patient care.** The harmful effects of presentations by pharmaceutical sales representatives sidetrack healthcare professionals from a fundamental goal, which is to offer patients the most appropriate treatments. This is yet another reason to follow the example of the 17% of general practitioners surveyed who refuse to see pharmaceutical sales representatives (4).

©Prescrire


.....  
**Selected references from Prescrire's literature search.**

1- Prescrire Editorial Staff "15 years of monitoring and one simple conclusion: don't expect sales representatives to help improve healthcare quality" *Prescrire Int* 2006; **15** (84): 154-159.

2- Spurling GK et al "Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review" *Plos Medicine* 2010; **7** (10): 22 pages.

3- "Visiteurs médicaux: le secteur ouvert à un réseau de médecins sentinelles" *Dépêche AFP*; 1 March 2013: 1 page.

4- Foisset E "Étude de l'impact de la visite médicale sur la qualité des prescriptions des médecins généralistes bretons" Medical thesis n°2912002, Brest, 2012: 181 pages.



**Prescrire**  
IN ENGLISH  
International

**Coming soon...**

**NEW PRODUCTS**

- Pasireotide in Cushing's disease
- Everolimus in breast cancer
- Axitinib in kidney cancer

**ADVERSE EFFECTS**

- Piriabedil
- Thrombotic risk of contraceptive transdermal patches

**REVIEWS**

- Antithrombotic drugs and ischaemic stroke
- Acupuncture and chronic joint pain

**Outlook**

- Euthanasia in Belgium, the Netherlands and Luxembourg